More Me-Too Drugs Please, FDA’s Jenkins Asks Industry
Executive Summary
FDA’s top new drug official called out industry’s innovation model, noting that major primary care markets are being left underserved as sponsors focus on precision medicine and rare diseases.
You may also be interested in...
Lilly’s Late-Stage CNS Pipeline Bare Following Edivoxetine Failure
Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.
What Innovation Crisis? First-In-Class Drug Approvals Stable For Almost 25 Years, FDA Says
An FDA study evaluating NMEs by level of innovation finds level first-in-class approvals to be consistent, and approvals after the study period reinforce “encouraging” findings. Analysis says new metric should be basis for assessment of programs created by FDASIA to speed development of innovative products.
Korean Biopharma Today And Tomorrow: M&A, Investment, Governance
Experts shared views at a recent conference in Seoul on how the Korean biopharma industry has evolved and what needs to be done to move forward in the next 10 years. Policy efficiency and family ownership in the sector came in for particular scrutiny, with some calling for sweeping changes.